BIO-TECHNE Corp

TECH 10-Q · Q3 2026
API behind this page

TECH Q3 2026 request

Playground key active
Request URL /api/financials?ticker=TECH&year=2026&quarter=3
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q3 2026 Q3 2025 YoY
Revenue 311,415 316,181 -1.5%
Show Product Lines breakouts
Consumables 257,338 257,785 -0.2%
Instruments 27,664 26,111 +5.9%
Product and Services 306,448 311,142 -1.5%
Royalty 4,967 5,039 -1.4%
Service 21,446 27,246 -21.3%
Show Business Segments breakouts
Diagnostics and Spatial Biology · Operating Segments 85,586 89,231 -4.1%
Protein Sciences · Operating Segments 226,154 227,687 -0.7%
Show Geography breakouts
APAC, excluding Greater China 21,820 21,245 +2.7%
CN 26,012 24,483 +6.2%
EMEA, excluding United Kingdom 73,446 66,501 +10.4%
GB 14,891 12,852 +15.9%
Rest of World 7,767 9,179 -15.4%
US 167,479 181,921 -7.9%
Show Consolidation Items breakouts
Intersegment Elimination -325 -737 +55.9%
Operating Segments 311,740 316,918 -1.6%
Cost of Revenue 103,127 101,625 +1.5%
Show Business Segments breakouts
Diagnostics and Spatial Biology · Operating Segments 38,649 37,189 +3.9%
Protein Sciences · Operating Segments 53,794 53,193 +1.1%
Gross Profit 208,288 214,556 -2.9%
Selling, General & Administrative 109,338 151,269 -27.7%
Show Business Segments breakouts
Diagnostics and Spatial Biology · Operating Segments 27,616 33,419 -17.4%
Protein Sciences · Operating Segments 57,909 55,804 +3.8%
Show Consolidation Items breakouts
Corporate Non Segment 3,802 2,013 +88.9%
Research And Development Expense Excluding Acquired In Process Cost 23,455 24,579 -4.6%
Show Business Segments breakouts
Diagnostics and Spatial Biology · Operating Segments 9,002 10,200 -11.7%
Protein Sciences · Operating Segments 14,452 14,780 -2.2%
Operating Expenses 132,793 175,848 -24.5%
Operating Income 75,495 38,708 +95.0%
Show Business Segments breakouts
Diagnostics and Spatial Biology · Operating Segments 10,319 8,423 +22.5%
Protein Sciences · Operating Segments 99,999 103,910 -3.8%
Show Consolidation Items breakouts
Operating Segments 110,318 112,333 -1.8%
Non-Operating Income (Expense) -4,270 -434 -883.9%
Income Before Taxes 71,225 38,274 +86.1%
Income Tax Expense (Benefit) 20,178 15,686 +28.6%
Net Income 51,047 22,588 +126.0%
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent -4,352 5,311 -181.9%
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent -160 -1,713 +90.7%
Other Comprehensive Income Loss Net Of Tax -4,512 3,598 -225.4%
Show Equity Components breakouts
Accumulated Other Comprehensive Income -4,512 3,598 -225.4%
Comprehensive Income 46,535 26,186 +77.7%
EPS (Basic) 0.33 0.14 +135.7%
EPS (Diluted) 0.32 0.14 +128.6%
Wtd Avg Shares (Basic) 156,327 157,372 -0.7%
Wtd Avg Shares (Diluted) 157,403 158,944 -1.0%
Revenue 311,415 316,181 -1.5%
Interest Expense -2,402 -2,007 -19.7%
Other Comprehensive Income (Q) — — —
Show Equity Components breakouts
Accumulated Net Unrealized Investment Gain Loss -160 -1,713 +90.7%
Accumulated Other Comprehensive Income -4,512 3,598 -225.4%
Accumulated Translation Adjustment -4,352 5,311 -181.9%
Net Income Loss Available To Common Stockholders Basic 51,037 22,585 +126.0%
Income Loss From Equity Method Investments -739 -589 -25.5%

Balance Sheet

Balance Sheet
Metric Q3 2026 Q3 2025 YoY
Current Assets
Cash & Cash Equivalents 209,819 140,670 +49.2%
Accounts Receivable 214,562 237,140 -9.5%
Inventory 201,175 191,083 +5.3%
Other Assets Current 62,494 53,647 +16.5%
Total Current Assets 688,050 627,240 +9.7%
Non-Current Assets
Property, Plant & Equipment 232,990 251,977 -7.5%
Operating Lease Right-of-Use Assets 68,316 — —
Goodwill 977,800 — —
Show Business Segments breakouts
Diagnostics and Spatial Biology 553,617 — —
Protein Sciences 424,183 — —
Other Non-Current Assets 264,371 268,987 -1.7%
Total Assets 2,550,601 2,644,259 -3.5%
Intangible Assets 319,074 443,699 -28.1%
Long Term Investments (Q) — — —
Show Schedule Of Equity Method Investment Equity Method Investee Name breakouts
Spear Bio · Other Noncurrent Assets 15 15 0.0%
Other Assets
Intangible Assets Net Excluding Goodwill 319,074 — —
Current Liabilities
Accounts Payable 23,490 31,644 -25.8%
Employee Related Liabilities Current 54,429 61,896 -12.1%
Accrued Liabilities 17,682 23,905 -26.0%
Deferred Revenue (Current) 38,433 32,269 +19.1%
Accrued Income Taxes Current 2,971 3,628 -18.1%
Operating Lease Liability Current 14,181 — —
Other Liabilities Current 2,092 1,813 +15.4%
Total Current Liabilities 153,278 169,204 -9.4%
Non-Current Liabilities
Deferred Tax Liabilities 14,210 — —
Operating Lease Liabilities 76,141 — —
Other Non-Current Liabilities 21,668 15,656 +38.4%
Other Liabilities
Long Term Debt And Capital Lease Obligations 200,000 330,000 -39.4%
Stockholders' Equity
Common Stock 1,565 1,568 -0.2%
Additional Paid In Capital Common Stock 1,005,403 902,124 +11.4%
Retained Earnings 1,145,192 1,196,385 -4.3%
Accumulated Other Comprehensive Income -66,856 -82,052 +18.5%
Total Stockholders' Equity 2,085,304 — —
Show Equity Components breakouts
Accumulated Other Comprehensive Income -66,856 -82,052 +18.5%
Accumulated Translation Adjustment -66,856 -85,369 +21.7%
Total Liabilities & Equity 2,550,601 2,644,259 -3.5%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q3 2026 YTD Q3 2025 YoY
Operating Activities
Net Income (Q) — — —
Show Equity Components breakouts
Retained Earnings 51,047 22,588 +126.0%
Net Income 127,241 91,078 +39.7%
Depreciation & Amortization 73,218 82,792 -11.6%
Deferred Income Taxes And Tax Credits 8,045 -18,825 +142.7%
Stock-Based Compensation 36,135 36,283 -0.4%
Equity Method Investment Realized Gain Loss On Disposal 335 169 +98.2%
Unrealized Gain Loss On Investments 2,334 — —
Asset Impairment Restructuring Charge 3,253 9,961 -67.3%
Noncash Portion Of Lease Expense -2,619 502 -621.7%
Recovery Of Assets Held For Sale -6,789 -3,655 -85.7%
Show Consolidation Items breakouts
Corporate Non Segment -6,789 -3,655 -85.7%
Other Operating Activities Cash Flow Statement 621 527 +17.8%
Increase Decrease In Accounts And Other Receivables -7,923 5,271 -250.3%
Change in Inventory -12,510 -11,540 -8.4%
Increase Decrease In Prepaid Expense 2,505 -7,217 +134.7%
Increase Decrease In Accounts Payable And Accrued Liabilities -2,953 -639 -362.1%
Increase Decrease In Employee Related Liabilities -11,199 12,006 -193.3%
Increase Decrease In Accrued Income Taxes Payable -13,037 -7,912 -64.8%
Net Cash from Operations 196,657 189,355 +3.9%
Investing Activities
Capital Expenditures -20,370 -26,116 +22.0%
Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital 4,620 2,653 +74.1%
Proceeds From Sale Of Property Held For Sale 4,617 1,789 +158.1%
Net Cash from Investing -11,133 -35,589 +68.7%
Financing Activities
Payments Of Dividends Common Stock -37,432 -38,004 +1.5%
Proceeds From Stock Options Exercised 58,193 45,513 +27.9%
Share Repurchases -24 -175,674 +100.0%
Repayments Of Lines Of Credit -146,000 -27,000 -440.7%
Tax Withholding for Share Compensation -10,643 -6,288 -69.3%
Net Cash from Financing -135,906 -163,453 +16.9%
Supplemental
Income Taxes Paid 42,355 55,899 -24.2%
Interest Paid 11,794 14,232 -17.1%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations -1,985 -1,434 -38.4%
Net Change in Cash 47,633 -11,121 +528.3%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 209,819 140,670 +49.2%

Values in thousands USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key